Background and Aim: Restoring ovulation, reducing weight, reducing circulating androgen levels, reducing the risk of miscarriage, and reducing the risk of gestational diabetes mellitus are some of the good deal of effects of metformin in Polycystic ovary syndrome (PCOS). The present study is aimed to provide the efficacy of metformin on clinical profile and metabolic disorders in women with PCOS attending a tertiary care setting.
Material and Methods: Present Observational study was conducted in Women with PCOS attending the outpatient department (OPD) of Gynaecology and endocrinology department of tertiary care setting. A total of 160 subjects were selected based on convenience and divided into two groups of 80, each based on inclusion criteria. Group A received metformin and group B received advice on lifestyle and diet modification. The parameters like body mass index (BMI), weight, hormonal imbalance, ovulation, and menstrual changes were analysed in both groups. Descriptive statistics for mean, SD were carried and chi-square test was used to test statistical significance.
Results: No significant difference was noted in mean BMI and weight before and after treatment between the study group (p Value>0.05), while there was a significant mean difference for parameters like fasting insulin, testosterone, LH, and LH: FSH (p Value0.05). No statistically significant difference was seen in the proportion of ovulation, before and after treatment, between the study group (p Value>0.05) but the proportion reduced to in the metformin group.
Conclusion: Compared with control interventions, metformin appears to be an effective intervention for overweight women with PCOS. Marked reduction in LH and insulin by metformin in our cases was a very significant observation. Metformin produces minimal changes in hirsutism and has the potential to alter the function of ovulation-inducing drugs.